Tri-Lo-Cyclen is a combined oral contraceptive, the effect of which is determined by the central and peripheral mechanisms. By means of gonadotropins’ secretion Suppression, it acts as prevention of the eggs maturation and ovulation, as a consequence. In addition, this birth control drug magnifies the viscosity of cervical mucus, which makes it difficult for sperm to enter the uterus, and has an influence on the epithelium of the endometrium, decreasing the possibility to attach to the uterine wall.
- Contraception (unwanted pregnancy prevention);
- Manifestations of a menopausal syndrome related to estrogen deficiency; female hypogonadism, dysmenorrhea;
- Palliative treatment of malignant tumors of the breast in the postmenopausal period;
- Common acne;
- Palliative treatment of malignant prostatic tumors.
Tri-Lo-Sprintec is a synthetic estrogen. It has an influence on the development of the uterine womb, fallopian tubes, secondary sexual characteristics. It also causes proliferative changes in the endometrium, increases the uterine sensitivity. It normalizes nitrogen metabolism, decreases the rating of lipids and cholesterol in the blood. It obtains a weak anabolic effect. It magnifies the calcium absorption and the formation of calcium channels in bones. If taken in high doses, it becomes a cause sodium and water retention.
It should be taken by adults orally. Tri-Lo-Sprintec dosage is 1 tablet daily, starting from the 5th day of the menstrual cycle (that is, the 5th day after the onset of menstruation). The package is comprised of 28 pills prescribed for a daily application without interruption (7 tablets contain ferrum or placebo). If menstruation is delayed, the occasion of pregnancy should be excluded.
At the onset of menstruation, the drug is resumed after 7 days after taking the last tablet of the previous cycle. If the background of a regular intake of menstruation does not occur, after excluding pregnancy the reception should be continued. If there are no two consecutive menstruations, pregnancy should be excluded before continuing.
- predisposition to any of Tri-Lo-Sprintec components;
- deep vein thrombosis, pulmonary thromboembolism;
- acute dysfunction of cerebral circulation;
- myocardial infarction;
- retinal artery thrombosis;
- angina pectoris or previous transferred ischemic attack;
- diabetes mellitus;
- hereditary dyslipoproteinemia;
- migraine with aura;
- diagnosed or suggested breast cancer;
- endometrial cancer or other diagnosed or suggested estrogen-dependent neoplasms;
- benign or malignant hepatic tumors;
- genital hemorrhages of unclear etiology;
- postmenopausal period;
- age under 18 years;
- the period after labor, especially the first 4 weeks;
- breastfeeding period;
- diagnosed or suggested pregnancy;
- jaundice during pregnancy;
- sickle-cell anemia;
- liver failure;
- hemolytic anemia;
- Cardiovascular system: hypertension, myocardial infarction, cerebral circulation disorders, deep vein thrombosis, arterial thromboembolism, thromboembolism of pulmonary or other types of the vessels, swelling of various etiology.
- Tumors: benign and malignant hepatic tumors, cervical and breast cancer.
- Hepatobiliary system: cholestatic jaundice, Budd-Chiari syndrome, intrahepatic cholestasis, cholelithiasis.
- Gastrointestinal tract: nausea, vomiting, pain in the abdominal, distended abdomen, colitis.
- Genital organs: intermenstrual hemorrhages, spotting allocations, amenorrhea, swings in the menstrual cycle, increased uterine fibroids, vaginal candidiasis, increased cervical secretion, cervical erosion, decreased libido, premenstrual syndrome, temporary infertility after the end of the drug intake
- Mammary glands: painful and tenderness sensations, galactorrhea, tenderness, size increase, reduction of lactation when applied immediately after birth.
- Skin: nodal fever, skin rash, chloasma, erythema multiforme, acne, seborrhea, alopecia, pilosis, pigmentation on the face, hypertrichosis, pemphigoid (gestational herpes).
- The visual organs: cataracts, lesions of the ophthalmic nerve, changes in the corneal curvature, a feeling of discomfort when wearing contact lenses.
- The central nervous system: headache, mood changes, irritability, depression, chorea.
- Metabolism: fluid retention, changes in body weight, decreased glucose tolerance, changes in appetite.
- Renal function: decreased kidney function, hemolytic-uremic syndrome.
- Others: dizziness, migraine.
- Taken with caution with inducers of hepatic metabolism: rifampicin, phenobarbital derivatives, anticonvulsants (phenytoin, carbamazepine), phenylbutazone, ketoconazole, a / b (broad-spectrum antibiotic) (with tetracyclines, ampicillin, chloramphenicol, neomycin).
- The contraceptive effect may be reduced with anticoagulants – derivatives of coumarin or indanedione with tricyclic antidepressants, maprotiline;
- Beta-blockers (increases the bioavailability and therefore the toxicity of these drugs);
- Oral antidiabetic drugs, insulin (there is a need to change the dosage);
- Bromocriptine – decreased efficacy, with hepatotoxic drugs, especially with dantrolene – the risk of increased hepatotoxicity, especially in women over 35 years of age.
If you miss a regular tablet (if more than 12 hours pass after the usual intake), you should use additional contraceptives (spermicide candles, creams, condoms, etc.) until the end of this cycle, while continuing to take the drug.
Tri-Lo-Sprintec is contraindicated in pregnancy and breastfeeding period.